NASDAQ: INBXV - Inhibrx, Inc.

Rentabilité sur six mois: 0%
Rendement en dividendes: 0.00%
Secteur: Нефтегаз

Calendrier des promotions Inhibrx, Inc.

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise Inhibrx, Inc.

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.

plus de détails
It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

IPO date 2024-05-28
Валюта usd
Сайт https://inhibrx.com
Цена ао 30.85
Changement de prix par jour: 0% (30.85)
Changement de prix par semaine: 0% (30.85)
Changement de prix par mois: 0% (30.85)
Changement de prix sur 3 mois: 0% (30.85)
Changement de prix sur six mois: 0% (30.85)
Evolution des prix depuis le début de l'année: 0% (30.85)
Tous les paramètres

Sous-estimation

Nom Signification Grade
P/S 0 0
P/BV 0 0
P/E 0 0
EV/EBITDA 0 0
Total: 2.5

Efficacité

Nom Signification Grade
ROA, % 0 0
ROE, % 0 0
Total: 0

Dividendes

Nom Signification Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Devoir

Nom Signification Grade
Debt/EBITDA 0 10
Total: 10

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % 0 0
Rentabilité Ebitda, % 0 0
Rentabilité EPS, % 0 0
Total: 0
Plus de détails



Superviseur Titre d'emploi Paiement Année de naissance
Mr. Mark Paul Lappe Founder, Chairman, President & CEO 1967 (58 années)
Dr. Brendan P. Eckelman Ph.D. Founder & Chief Scientific Officer 1979 (46 années)
Mr. Quinn L. Deveraux Founder
Dr. Ashraf Amanullah Executive VP & Chief Technical Operations Officer 1968 (57 années)
Ms. Leah Pollema J.D. VP, Corporate Secretary & General Counsel
Dr. Charbel Helaihel Pharm.D. Vice President of Marketing & Commercial Planning
Mr. Jeffrey J. Jensen Executive VP & Chief Clinical Operations Officer
Mr. David Matly M.B.A. Executive VP and Chief Commercial & Business Development Officer
Dr. Carlos Bais Ph.D. Executive Vice President of Translational Sciences
Dr. Josep Garcia Ph.D. EVP & Chief Clinical Development Officer

Adresse: United States, La Jolla, 11025 North Torrey Pines Road - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://inhibrx.com